AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18461016
Drug: Valacyclovir 1
RxNorm normalized name: valacyclovir 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 1 g once daily for 24 weeks
Trial: 3046553
Drug: Clozapine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (up to 900 mg/d)
Trial: 3046553
Drug: Chlorpromazine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (up to 1800 mg/d)
Trial: 27738832
Drug: Atorvastatin emulgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin emulgel (2%)
Trial: 30655509
Drug: Second-generation antipsychotic
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antipsychotic drug amisulpride
Trial: 25130768
Drug: Cold moisturizing
RxNorm normalized name: Sudafed OM Sinus Cold Moisturizing 0.05% Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold moisturizing formulation
Trial: 10529659
Drug: Moderately early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately early dexamethasone group (14 days, total dose 4.75 mg/kg)
Trial: 10529659
Drug: Early dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Early dexamethasone group (7 days, total dose 2.38 mg/kg)
Trial: 2694418
Drug: Theophylline (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (5, 10, and 15 mg/l)
Trial: 866904
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg indomethacin with 10 mg diazepam
Trial: 28655793
Drug: Ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 10 mg/kg every 3 weeks for four doses, then 10 mg/kg every 12 weeks for up to 3 years
Trial: 17121726
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (2 ml)
Trial: 12767733
Drug: Topiramate (25-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (25-300 mg per day)
Trial: 9109860
Drug: cM-T412 (anti-CD4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cM-T412 (anti-CD4 antibody)
Trial: 8258118
Drug: Perycit, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perycit, 500 mg, tid, for 3 months
Trial: 8258118
Drug: Trental, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trental, 100 mg, tid, for 3 months
Trial: 23467055
Drug: bifonazole-urea ointment
RxNorm normalized name: bifonazole / urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bifonazole-urea ointment
Trial: 23467055
Drug: 40% urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% urea ointment with plastic dressing
Trial: 16941973
Drug: Auricular point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular point pressing therapy
Trial: 11344213
Drug: Glucosamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosamine infusion (4 micromol/dL.min) from 90-240 min (n=6)
Trial: 11344213
Drug: Glucosamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosamine infusion (4 micromol/dL.min) from 0-300 min (n=6)
Trial: 8157786
Drug: Thymopentin (Timunox),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin (Timunox), 50 mg, thrice-weekly subcutaneous injections
Trial: 2893314
Drug: High-dose intraventricular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intraventricular bethanechol (1.75 mg/d)
Trial: 29429800
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by radical surgery with or without adjuvant treatment (NACT group, n = 39)
Trial: 29429800
Drug: Radical surgery
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical surgery with or without adjuvant treatment (RH group, n = 25)
Trial: 16816554
Drug: Apricitabine 800
RxNorm normalized name: cobicistat 150 MG / darunavir 800 MG / emtricitabine 200 MG / tenofovir alafenamide 10 MG [Symtuza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apricitabine 800 mg/day
Trial: 16816554
Drug: Apricitabine 1200
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apricitabine 1200 mg/day
Trial: 16816554
Drug: Apricitabine 1600
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apricitabine 1600 mg/day
Trial: 31441409
Drug: Shenfu group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu group (received 60 mL Shenfu injection infusion for 7 days)
Trial: 26645521
Drug: Resistant Starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant Starch (RS2) 10 g/d for 8 weeks
Trial: 21465247
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO3) ingestion (0.3 g kg(‐1) body weight)
Trial: 2647535
Drug: 2% ketanserin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% ketanserin ointment
Trial: 10884197
Drug: Cup with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cup with cluster holes for adjunctive screw fixation (n = 30)
Trial: 16417773
Drug: Penyanqing Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penyanqing Capsule (PYQC), 3 times a day, 4 capsules each time, for 2 months
Trial: 16417773
Drug: Fuyankang tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuyankang tablets (FYKT), 3 times a day, 6 tablets each time, for 2 months
Trial: 12847648
Drug: Lösferron (ferrous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lösferron (ferrous gluconate, Lilly Pharma, Hamburg) - 0.5 l
Trial: 12847648
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral contrast agent
Trial: 12782900
Drug: Stepped-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped-care treatment
Trial: 27189657
Drug: 0.01 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01 mL/kg dose of 10% fluorescein sodium
Trial: 27189657
Drug: 0.02 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mL/kg dose of 10% fluorescein sodium
Trial: 22708649
Drug: TBV administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBV administered concurrently with PIFN (standard dosing arm)
Trial: 22708649
Drug: TBV 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBV 600 mg BID monotherapy for 4 weeks followed by combination therapy with PIFN (pre-dosing arm)
Trial: 20063435
Drug: S90049 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S90049 (60 mg)
Trial: 7894919
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EAP + RNB
Trial: 25812128
Drug: Paced Auditory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paced Auditory Serial Addition Test (PASAT) administered to patients with MS
Trial: 25812128
Drug: Paced Auditory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paced Auditory Serial Addition Test (PASAT) administered to normal controls
Trial: 23669304
Drug: Alginate-antacid (Gaviscon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate-antacid (Gaviscon Double Action Liquid)
Trial: 16955187
Drug: Oral inosiplex
RxNorm normalized name: Inosiplex
DrugBank: Inosine pranobex (DB13156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inosiplex (50 mg/kg/day in five divided doses for 12 weeks)
Trial: 11720426
Drug: Accelerated chemotherapy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated chemotherapy with EVI and GM-CSF support (Arm B)
Trial: 11720426
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy with EVI (Arm A)
Trial: 11720426
Drug: Accelerated chemotherapy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated chemotherapy with EVI and oral antibiotics (Arm C)
Trial: 12127385
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil treatment
Trial: 8238379
Drug: FK‐453 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK‐453 (200 mg)
Trial: 25675169
Drug: Transconjunctival local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transconjunctival local anesthesia with 2% lidocaine gel
Trial: 22305809
Drug: Probucol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (1000 mg orally before angioplasty and 500 mg twice daily for 3 days after intervention)
Trial: 18807007
Drug: Balanced 6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced 6% HES 130/0.42 plus a balanced crystalloid solution
Trial: 14607210
Drug: Ximelagatran plus
RxNorm normalized name: XIMELAGATRAN
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran plus aspirin
Trial: 10741624
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg)
Trial: 31291710
Drug: Vaccination 2
RxNorm normalized name: VACCINES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination 2 weeks before chemotherapy (Arm A)
Trial: 31291710
Drug: Vaccination on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination on the first day of chemotherapy (Arm B)
Trial: 27910086
Drug: Transfusion at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion at a lower haemoglobin threshold of 70 g/l
Trial: 25733335
Drug: Revised major
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revised major purgative decoction (100 ml infused through the decompression tube, three times daily)
Trial: 25733335
Drug: Neostigmine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.5 mg by muscle injection, twice daily)
Trial: 12466030
Drug: D-cycloserine 50
RxNorm normalized name: D-(+)-cycloserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine 50 mg/d
Trial: 9642886
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (CT) training
Trial: 9642886
Drug: Supportive-expressive dynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive dynamic therapy (SE) training
Trial: 9642886
Drug: Individual drug
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual drug counseling training
Trial: 9642886
Drug: Drug counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug counseling training
Trial: 6759139
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg diclofenac-Na daily in 3 doses for 21 days
Trial: 29395870
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural therapy (ICBT)
Trial: 27765610
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tPCS and tDCS
Trial: 26074314
Drug: EPA 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA 1.8 g/day
Trial: 26074314
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil 6.0 g/day
Trial: 26488347
Drug: Fluoxetine 40
RxNorm normalized name: fluoxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 40 mg/day (bulimic patients)
Trial: 17205469
Drug: Standard melarsoprol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard melarsoprol therapy (3 series of 3.6 mg/kg/day iv for 3 days, with 7-day breaks between series)
Trial: 17205469
Drug: Nifurtimox monotherapy
RxNorm normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifurtimox monotherapy for 14 days (5 mg/kg orally 3 times per day)
Trial: 9609370
Drug: micro screw
RxNorm normalized name: Lipantil Micro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: micro screw with intra-oral autologous bone
Trial: 2646258
Drug: Requiring ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Requiring ≥ 1/3 of treatments to satisfy the discriminant equation
Trial: 21995882
Drug: Lidocaine patch
RxNorm normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine patch (5%)
Trial: 16968347
Drug: naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naltrexone (50 mg/day)
Trial: 16968347
Drug: acamprosate (1998
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acamprosate (1998 mg/day)
Trial: 12490770
Drug: Paroxetine (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20-40 mg/day)
Trial: 14567887
Drug: Cetrorelix (GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix (GnRH antagonist) 3 mg
Trial: 3549869
Drug: Amitriptyline (150-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (150-300 mg/day)
Trial: 3549869
Drug: Desipramine (150-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (150-300 mg/day)
Trial: 3549869
Drug: Low-dose desipramine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose desipramine (50 mg)
Trial: 3549869
Drug: Low-dose amitriptyline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose amitriptyline (50 mg)
Trial: 17372696
Drug: Indium chloride
RxNorm normalized name: indium chloride In-111
DrugBank: Indium In-111 chloride (DB09490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indium chloride adsorbed onto activated charcoal, entrapped in cellulose acetate polymer melt; specific dosage and duration not mentioned.
Trial: 15783255
Drug: Antifibrinolytic agents
RxNorm normalized name: ANTIFIBRINOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifibrinolytic agents
Trial: 29304768
Drug: Long-lasting vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-lasting vaginal Lactobacillus rhamnosus BMX 54 administration (6 months)
Trial: 25659520
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg rectal morphine
Trial: 20580572
Drug: Propofol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5 to 3.5 mg/kg/h)
Trial: 18167121
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG (LGG) 5 x 10(9) colony-forming units twice daily for 4-6 weeks before delivery and 6 months post-natal
Trial: 12623165
Drug: Gliclazide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide (10 microg/ml)
Trial: 12623165
Drug: Gliclazide (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide (5-10 microg/ml)
Trial: 22840917
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin 2 g
Trial: 18538913
Drug: GC Tooth
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC Tooth Mousse (commercial re-mineralizing treatment)
Trial: 9087480
Drug: Cefdinir, 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefdinir, 7 mg/kg of body weight twice a day for 10 days
Trial: 9087480
Drug: Cephalexin, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin, 10 mg/kg four times a day for 10 days
Trial: 8384645
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II (5 ng/kg per min) infusion for 60 minutes
Trial: 8384645
Drug: Enalaprilat (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat (1 mg intravenously) administration
Trial: 8384645
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control infusion
Trial: 8384645
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control administration
Trial: 28399799
Drug: Sugammadex 2
RxNorm normalized name: sugammadex 200 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2 mg/kg with neostigmine 50 μg/kg (Group NS)
Trial: 19165436
Drug: Standard Conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Conservative Treatment (SCT)
Trial: 16442888
Drug: Pravastatin, Simvastatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin, Simvastatin, Atorvastatin
Trial: 15534165
Drug: Fluviral S/F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluviral S/F (Shire Biologics)
Trial: 8489326
Drug: Phenelzine sulfate
RxNorm normalized name: Phenelzine Sulfate
DrugBank: Phenelzine (DB00780)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenelzine sulfate (average dose, 60 mg/d)
Trial: 3031150
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone for group A
Trial: 3031150
Drug: Prolonging therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonging therapy beyond 10 days by switching to the alternate corticoid drug
Trial: 3031150
Drug: Initial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial therapy period
Trial: 3031150
Drug: Continuing therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuing therapy beyond initial treatment
Trial: 29558423
Drug: GA +
RxNorm normalized name: Sea-Omega + D Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GA + Metformin (GA + Met)
Trial: 22124612
Drug: Experimental gingivitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental gingivitis (E-I test quadrants) induced by oral hygiene abstention for 21 days
Trial: 10360371
Drug: Lisofylline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisofylline (3 mg/kg every 6 h i.v.)
Trial: 1786587
Drug: Olbetam (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olbetam (250 mg 3 x per day for 3 months)
Trial: 31351488
Drug: High-dose bio-optimized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bio-optimized Curcuma longa extract (BCL)
Trial: 31351488
Drug: Low-dose bio-optimized
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bio-optimized Curcuma longa extract (BCL)
Trial: 26901576
Drug: PedaTyph™ vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PedaTyph™ vaccine (2 doses at 6 weeks interval)
Trial: 26901576
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (vaccines as per national guidelines)
Trial: 26901576
Drug: PedaTyph™ vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PedaTyph™ vaccine
Trial: 22241898
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (anthracycline-based)
Trial: 3975851
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy (control group)
Trial: 17392721
Drug: Laropiprant 30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laropiprant 30, 100, and 300 mg coadministered with extended-release niacin
Trial: 11919330
Drug: multisensory stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multisensory stimulation including 1 mL 33% oral glucose
Trial: 10067815
Drug: Helicobacter pylori
RxNorm normalized name: HELICOBACTER PYLORI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helicobacter pylori eradication followed by daily dietary supplementation with antioxidant micronutrients
Trial: 7564362
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (5 mg ramipril and 6 mg piretanide)
Trial: 28596274
Drug: Nitrate supplementation
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate supplementation (70 ml, 0.4 g nitrate)
Trial: 28596274
Drug: Nitrate-depleted (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-depleted (70 ml, 0 g nitrate)
Trial: 25901481
Drug: Remoxy 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxy 20 mg
Trial: 25901481
Drug: Remoxy 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxy 10 mg
Trial: 31975502
Drug: Topical serum
RxNorm normalized name: BIOTIN 4 g in 50 mL TOPICAL OIL [Biotn Topical Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical serum containing vitamin C, vitamin E, and raspberry leaf cell culture extract
Trial: 18422592
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol 1000 mg